Saturday, May 31, 2025

Latest

Revive Therapeutics Sees FDA Recommend Phase 3 For COVID-19 Related Study Of Bucillamine

Revive Therapeutics (CSE: RVV) announced major news this morning related to its ongoing study of Bucillamine, with the US Food and Drug Administration recommending that the company proceed straight to a phase three confirmatory clinical trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection.

The news is significant as it means that Revive will be able to skip over the phase two clinical study portion of the FDA’s process, enabling the product to get to market sooner than expected if proven effective against the infectious disease. The push to phase three on the study of Bucillamine will enable the company to expeditiously evaluate the safety and efficacy of the drug.

In addition to the recommendation provided, the FDA also provided guidance on the study design and outcome measures for the phase 3 study. More importantly, the FDA identified that as a result of Revive’s previous work with the drug on the treatment of gout, the data provided from that study could be used to skip over phase 1 and 2 of the clinical study process. The firms contract research team, Pharm-Olam, is actively working towards assembling the final investigation new drug (IND) for submission to the FDA within the next 60 days, after which the firm will begin its phase 3 trials.

Revive Therapeutics last traded at $0.18 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

European Car Sales Drop to Record Low, Manufacturers to Gradually Resume Operations

Given the widespread lockdowns and rising unemployment levels around the world, consumers are opting to...

Sunday, April 19, 2020, 12:00:00 PM

Biotech Boom Playbook, Part Two: The Structure

The degree to which a compelling biotech story is able to create lift in the...

Tuesday, May 26, 2020, 04:16:08 PM

Nearly 25% Of Household Income In The US Comes From Coronavirus Government Payments

As the US economy crumbled under the weight of the pandemic, unemployment numbers soared, and...

Sunday, August 2, 2020, 11:30:00 AM

Airbnb Facing Financial Difficulty, Lays off 25% of Workforce

As the coronavirus pandemic continues to ravage economies around the world, some industries are being...

Wednesday, May 6, 2020, 04:44:00 PM

Oil Benchmark Briefly Sinks Below $20 In Sunday Evening Trading

The price of West Texas Intermediate (WTI), a benchmark for the price of oil, has...

Sunday, March 29, 2020, 08:44:48 PM